INCY

Incyte Corporation Press Releases

$85.85
*  
1.69
1.93%
Get INCY Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading INCY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer
2/26/2015 7:30:00 AM - Business Wire


Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study
2/23/2015 7:00:00 AM - PR Newswire


Shareholders of Synacor Nominate Three Highly Qualified Directors for Election at Synacor''s 2015 Annual Meeting of Stockholders
2/23/2015 7:00:00 AM - PR Newswire


Incyte to Present at Upcoming Investor Conferences
2/17/2015 8:00:00 AM - Business Wire


Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs
2/12/2015 7:00:00 AM - Business Wire


Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
2/11/2015 7:30:00 AM - GlobeNewswire


Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
1/28/2015 5:00:00 PM - Business Wire
▲5.42 % Price Change since this news event. The Volume Ratio is 0.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
1/27/2015 8:00:00 AM - Business Wire
▲3.48 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
1/23/2015 7:35:00 AM - Business Wire
▲10.62 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Board Appoints Two New Directors
1/9/2015 8:00:00 AM - Business Wire
▲17.20 % Price Change since this news event. The Volume Ratio is 1.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m. EST
1/9/2015 7:26:00 AM - Business Wire


Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
1/9/2015 7:00:00 AM - Business Wire


Verastem Provides Year-End 2014 Update and Outlook for 2015
1/8/2015 4:01:00 PM - Business Wire


Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference
12/23/2014 8:00:00 AM - Business Wire
▲13.23 % Price Change since this news event. The Volume Ratio is 1.41.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
12/9/2014 7:00:00 AM - PR Newswire


Jakafi® (ruxolitinib) receives expanded approval for treatment of polycythemia vera; available through Diplomat
12/5/2014 4:35:00 PM - PR Newswire


FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
12/4/2014 10:55:00 AM - Business Wire
▲16.17 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
12/2/2014 1:15:00 AM - Business Wire
▲15.62 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day